{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:33Z","timestamp":1792788093872,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karolinska Institute","id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several gene expression signatures (GESs) are used for risk stratification in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative (ER-positive\/HER2-negative) early breast cancer. Recent integrative approaches combine tumour proliferation, estrogen receptor signalling, immune activity, and clinicopathologic features, yielding gains in prognostic accuracy. We therefore developed a machine-learning-based clinicogenomic prognostic model integrating a research-grade implementation of an established GES with immune-related and clinicopathologic features to improve prognostic stratification in ER-positive\/HER2-negative early breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective integrative analysis of publicly available and institutional microarray and RNA-sequencing data included four independent datasets of systemically untreated or endocrine-treated patients (n = 5132). One dataset was used for the development of a random survival forest (RSF) model, and three datasets were used for external validation. The RSF model incorporated a research-grade implementation of the 21-gene recurrence score (RS), the 14-gene immunoglobulin signature, and clinicopathologic features. Model performance was evaluated relative to the standalone research-grade implementation of the 21-gene RS using measures of risk stratification, discrimination, and prediction error. Feature contributions were examined using time-dependent explainability analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In external validation, the RSF model identified larger low-risk groups than the standalone 21-gene RS, with relative increases of 33.8 to 111.8%, while maintaining similar or higher horizon-specific survival estimates. The RSF model also improved discrimination over the standalone 21-gene RS across validation datasets, with absolute increases of 0.035 to 0.058 in the concordance index and 0.030 to 0.064 in the integrated area under the time-dependent receiver operating characteristic curve. Risk separation, measured by the difference in restricted mean survival time, was consistently greater for the RSF model, whereas prediction error was comparable or lower according to Cox-recalibrated integrated Brier score. Explainability analyses indicated time-dependent feature contributions, with the 21-gene RS and clinicopathologic variables driving early prognostic performance and the immune component contributing a smaller but more stable effect over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This explainable clinicogenomic machine learning model integrates research-grade molecular, immune-related, and clinicopathologic features and improves prognostic stratification in retrospective ER-positive\/HER2-negative early breast cancer datasets. These findings support its potential as a more informative and biologically grounded approach to early breast cancer risk assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02388-4","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:44:26Z","timestamp":1789587866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a machine learning clinicogenomic model to improve prognostic stratification in ER-positive\/HER2-negative early breast cancer"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-6525","authenticated-orcid":false,"given":"Michail","family":"Sarafidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9919-4471","authenticated-orcid":false,"given":"Emmanouil G.","family":"Sifakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-1847","authenticated-orcid":false,"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-9987","authenticated-orcid":false,"given":"Theodoros","family":"Foukakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4122-9624","authenticated-orcid":false,"given":"Alexios","family":"Matikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","volume":"40","author":"F Andre","year":"2022","unstructured":"Andre F, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:1816\u201337.","journal-title":"J Clin Oncol"},{"key":"2388_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2023","unstructured":"Loibl S, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up(dagger). Ann Oncol Off J Eur Soc Med Oncol. 2023;35:159.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2388_CR3","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/annonc\/mdz126","volume":"30","author":"A Matikas","year":"2019","unstructured":"Matikas A, Foukakis T, Swain S, Bergh J. Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet? Ann Oncol. 2019;30:1044\u201350.","journal-title":"Ann Oncol"},{"key":"2388_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10549-019-05226-8","volume":"176","author":"I Sestak","year":"2019","unstructured":"Sestak I, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019;176:377\u201386.","journal-title":"Breast Cancer Res Treat"},{"key":"2388_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00738-7","volume":"11","author":"MB Jensen","year":"2025","unstructured":"Jensen MB, et al. Prosigna risk of recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer. NPJ Breast Cancer. 2025;11:26.","journal-title":"NPJ Breast Cancer"},{"key":"2388_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"KS Albain","year":"2010","unstructured":"Albain KS, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55\u201365.","journal-title":"Lancet Oncol"},{"key":"2388_CR7","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726\u201334.","journal-title":"J Clin Oncol"},{"key":"2388_CR8","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336\u201347.","journal-title":"N Engl J Med"},{"key":"2388_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/JCO.20.00853","volume":"39","author":"R Buus","year":"2021","unstructured":"Buus R, et al. Molecular drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: a TransATAC study. J Clin Oncol. 2021;39:126\u201335.","journal-title":"J Clin Oncol"},{"key":"2388_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2124","volume":"10","author":"P Wirapati","year":"2008","unstructured":"Wirapati P, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10:R65.","journal-title":"Breast Cancer Res"},{"key":"2388_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jamaoncol.2017.5524","volume":"4","author":"I Sestak","year":"2018","unstructured":"Sestak I, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:545\u201353.","journal-title":"JAMA Oncol"},{"key":"2388_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.20.03007","volume":"39","author":"JA Sparano","year":"2021","unstructured":"Sparano JA, et al. Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol. 2021;39:557\u201364.","journal-title":"J Clin Oncol"},{"key":"2388_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104744","author":"R Stein","year":"2025","unstructured":"Stein R, et al. 190O Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study. ESMO Open. 2025. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104744.","journal-title":"ESMO Open"},{"key":"2388_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1466017","volume":"7","author":"A Matikas","year":"2018","unstructured":"Matikas A, et al. Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. Oncoimmunology. 2018;7:e1466017.","journal-title":"Oncoimmunology"},{"key":"2388_CR15","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1158\/1078-0432.CCR-19-1131","volume":"25","author":"A Matikas","year":"2019","unstructured":"Matikas A, et al. Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data. Clin Cancer Res. 2019;25:5717\u201326.","journal-title":"Clin Cancer Res"},{"key":"2388_CR16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/1878-0261.12654","volume":"14","author":"I Zerdes","year":"2020","unstructured":"Zerdes I, et al. Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. Mol Oncol. 2020;14:951\u201363.","journal-title":"Mol Oncol"},{"key":"2388_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.annonc.2024.10.012","volume":"36","author":"M Martin","year":"2025","unstructured":"Martin M, et al. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy. Ann Oncol. 2025;36:158\u201371.","journal-title":"Ann Oncol"},{"key":"2388_CR18","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(25)00276-1","volume":"26","author":"G Villacampa","year":"2025","unstructured":"Villacampa G, et al. HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis. Lancet Oncol. 2025;26:1100\u201312.","journal-title":"Lancet Oncol"},{"key":"2388_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0318167","volume":"20","author":"TG Baidoo","year":"2025","unstructured":"Baidoo TG, Rodrigo H. Data-driven survival modeling for breast cancer prognostics: a comparative study with machine learning and traditional survival modeling methods. PLoS ONE. 2025;20:e0318167.","journal-title":"PLoS ONE"},{"key":"2388_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00897-6","author":"B Reardon","year":"2026","unstructured":"Reardon B, Culhane AC, Van Allen EM. Convergence of machine learning and genomics for precision oncology. Nat Rev Cancer. 2026. https:\/\/doi.org\/10.1038\/s41568-025-00897-6.","journal-title":"Nat Rev Cancer"},{"key":"2388_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.","journal-title":"PLoS Med"},{"key":"2388_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001216","volume":"9","author":"DG Altman","year":"2012","unstructured":"Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med. 2012;9:e1001216.","journal-title":"PLoS Med"},{"key":"2388_CR23","doi-asserted-by":"publisher","first-page":"8770","DOI":"10.1038\/s41598-019-45165-4","volume":"9","author":"DMA Gendoo","year":"2019","unstructured":"Gendoo DMA, et al. MetaGxData: clinically annotated breast, ovarian and pancreatic cancer datasets and their use in generating a multi-cancer gene signature. Sci Rep. 2019;9:8770.","journal-title":"Sci Rep"},{"key":"2388_CR24","doi-asserted-by":"publisher","first-page":"7512","DOI":"10.1158\/1078-0432.CCR-17-1535","volume":"23","author":"A Lundberg","year":"2017","unstructured":"Lundberg A, et al. Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts. Clin Cancer Res. 2017;23:7512\u201320.","journal-title":"Clin Cancer Res"},{"key":"2388_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1325","volume":"7","author":"Y Pawitan","year":"2005","unstructured":"Pawitan Y, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7:R953.","journal-title":"Breast Cancer Res"},{"key":"2388_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00465-3","volume":"8","author":"J Staaf","year":"2022","unstructured":"Staaf J, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8:94.","journal-title":"NPJ Breast Cancer"},{"key":"2388_CR27","doi-asserted-by":"publisher","first-page":"7178","DOI":"10.3390\/ijms21197178","volume":"21","author":"AS Heimes","year":"2020","unstructured":"Heimes AS, et al. Prognostic significance of interferon-gamma and its signaling pathway in early breast cancer depends on the molecular subtypes. Int J Mol Sci. 2020;21:7178.","journal-title":"Int J Mol Sci"},{"key":"2388_CR28","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/bioinformatics\/btv693","volume":"32","author":"DM Gendoo","year":"2016","unstructured":"Gendoo DM, et al. Genefu: an R\/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics. 2016;32:1097\u20139.","journal-title":"Bioinformatics"},{"key":"2388_CR29","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/nprot.2009.97","volume":"4","author":"S Durinck","year":"2009","unstructured":"Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the R\/Bioconductor package biomaRt. Nat Protoc. 2009;4:1184\u201391.","journal-title":"Nat Protoc"},{"key":"2388_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqaf131","volume":"7","author":"Q Yang","year":"2025","unstructured":"Yang Q, Hartman J, Sifakis EG. BreastSubtypeR: a unified R\/Bioconductor package for intrinsic molecular subtyping in breast cancer research. NAR Genom Bioinform. 2025;7:lqaf131.","journal-title":"NAR Genom Bioinform"},{"key":"2388_CR31","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817\u201326.","journal-title":"N Engl J Med"},{"key":"2388_CR32","doi-asserted-by":"publisher","first-page":"9155","DOI":"10.1158\/0008-5472.CAN-05-2553","volume":"65","author":"B Weigelt","year":"2005","unstructured":"Weigelt B, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005;65:9155\u20138.","journal-title":"Cancer Res"},{"key":"2388_CR33","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-11-0926","volume":"17","author":"M Filipits","year":"2011","unstructured":"Filipits M, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17:6012\u201320.","journal-title":"Clin Cancer Res"},{"key":"2388_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-4-3","volume":"4","author":"C Fan","year":"2011","unstructured":"Fan C, et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics. 2011;4:3.","journal-title":"BMC Med Genomics"},{"key":"2388_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2022.01.031","volume":"166","author":"RD Gelber","year":"2022","unstructured":"Gelber RD, et al. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: a subpopulation treatment effect pattern plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. Eur J Cancer. 2022;166:219\u201328.","journal-title":"Eur J Cancer"},{"key":"2388_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41523-022-00492-0","volume":"8","author":"T Qing","year":"2022","unstructured":"Qing T, et al. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. NPJ Breast Cancer. 2022;8:119.","journal-title":"NPJ Breast Cancer"},{"key":"2388_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v077.i01","volume":"77","author":"MN Wright","year":"2017","unstructured":"Wright MN, Ziegler A. Ranger: a fast implementation of random forests for high dimensional data in C++ and R. J Stat Softw. 2017;77:1\u201317.","journal-title":"J Stat Softw"},{"key":"2388_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152.","journal-title":"BMC Med Res Methodol"},{"key":"2388_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad723","author":"M Spytek","year":"2023","unstructured":"Spytek M, et al. Survex: an R package for explaining machine learning survival models. Bioinformatics. 2023. https:\/\/doi.org\/10.1093\/bioinformatics\/btad723.","journal-title":"Bioinformatics"},{"key":"2388_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.knosys.2022.110234","volume":"262","author":"M Krzyzi\u0144ski","year":"2023","unstructured":"Krzyzi\u0144ski M, Spytek M, Baniecki H, Biecek P. SurvSHAP (t): time-dependent explanations of machine learning survival models. Knowl Based Syst. 2023;262:110234.","journal-title":"Knowl Based Syst"},{"key":"2388_CR41","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836\u201346.","journal-title":"N Engl J Med"},{"key":"2388_CR42","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s43018-023-00527-w","volume":"4","author":"S Onkar","year":"2023","unstructured":"Onkar S, et al. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nat Cancer. 2023;4:516\u201334.","journal-title":"Nat Cancer"},{"key":"2388_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104109","volume":"10","author":"L Angelats","year":"2025","unstructured":"Angelats L, et al. Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer. ESMO Open. 2025;10:104109.","journal-title":"ESMO Open"},{"key":"2388_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0116-8","volume":"5","author":"P Poudel","year":"2019","unstructured":"Poudel P, Nyamundanda G, Patil Y, Cheang MCU, Sadanandam A. Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. NPJ Breast Cancer. 2019;5:21.","journal-title":"NPJ Breast Cancer"},{"key":"2388_CR45","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/annonc\/mds080","volume":"23","author":"A Prat","year":"2012","unstructured":"Prat A, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol. 2012;23:2866\u201373.","journal-title":"Ann Oncol"},{"key":"2388_CR46","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1056\/NEJMoa052933","volume":"355","author":"C Fan","year":"2006","unstructured":"Fan C, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355:560\u20139.","journal-title":"N Engl J Med"},{"key":"2388_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148957","volume":"11","author":"E Laas","year":"2016","unstructured":"Laas E, et al. Low concordance between gene expression signatures in ER positive HER2 negative breast carcinoma could impair their clinical application. PLoS ONE. 2016;11:e0148957.","journal-title":"PLoS ONE"},{"key":"2388_CR48","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(24)01745-8","volume":"404","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2024","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials. Lancet. 2024;404:1407\u201318.","journal-title":"Lancet"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02388-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02388-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02388-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:05:31Z","timestamp":1789589131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02388-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02388-4","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee in Stockholm approved the gene expression analyses conducted in the three cohorts comprising the institutional Stockholm Breast Cancer Cohorts (dnr 2006\/394-31\/3, 2006\/1183-31\/2 and amendments 2018\/789-32, 2018\/790-32; dnr 148-93 and amendment 2002\/02-260; dnr 2001\/01-139). All other gene expression and clinical data were obtained from publicly available repositories, and no additional ethics permits were required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexios Matikas: speaker (no personal fees): Roche, Seagen, Astra Zeneca; consultant (no personal or institutional fees): Roche, Astra Zeneca, Veracyte; research funding paid to institution by Merck, Astra Zeneca, Novartis, Veracyte; advisory board: Nordic Pharma (no personal or institutional fees). Jonas Bergh: research funding to institution (Karolinska Institutet and\/or Karolinska University Hospital) from Amgen, Astra Zeneca, Bayer, Merck, Pfizer, Roche and Sanofi; honoraria from UpToDate paid to Asklepios Medicin HB; head of advisory board at Stratipath AB; Coronis and Asklepios Cancer Research AB hold shares of Stratipath AB; honoraria for lectures \/ educational conferences for postgraduate courses from Astra Zeneca paid to Coronis and Asklepios Cancer Research AB, chairmanship for meetings arranged by Akademikonferens on behalf of Roche, and lectures for Novartis and Gilead, respectively; honoraria to Coronis and Asklepios Cancer Research AB for both activities. Theodoros Foukakis: invited Speaker, Payment to Institution: Roche, Astra Zeneca, Gilead Sciences, Novartis, Daiichi Sankyo, Bristol Myers Squibb; royalties, personal: Wolters Kluwer (authorship of two chapters in UpToDate); clinical trial support to Institution: Astra Zeneca, Coordinating PI (research grant and study drug), Novartis, Coordinating PI (research grant and study drug), Veracyte, Coordinating PI (discount on the ProsignaPAM50 assay in ARIADNE clinical trial). All the other authors had no potential conflicts of interest to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"156"}}